Trial Profile

Does therapy with an inhaled combination of fluticasone and salmeterol improve clinical outcomes and compliance with taking asthma medication in patients with asthma?

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate; Salmeterol
Indications Asthma
Focus Therapeutic Use
Sponsors GlaxoSmithKline; GSK

Most Recent Events

05 Apr 2012 Official Title amended as reported by Australian New Zealand Clinical Trials Registry record.
05 Apr 2012 Actual initiation date changed from May 2006 to Feb 2007 as reported by Australian New Zealand Clinical Trials Registry record.
29 Aug 2011 Actual initiation date Mar 2006 added as reported by Australian New Zealand Clinical Trials Registry.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com